Meeder Asset Management Inc. Acquires Shares of 15,137 Kodiak Sciences Inc. (NASDAQ:KOD)

Meeder Asset Management Inc. bought a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,137 shares of the company’s stock, valued at approximately $36,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of KOD. Acadian Asset Management LLC boosted its position in shares of Kodiak Sciences by 14.1% during the second quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock valued at $4,614,000 after buying an additional 242,559 shares during the period. Vanguard Group Inc. boosted its holdings in Kodiak Sciences by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock valued at $8,702,000 after acquiring an additional 10,978 shares during the period. Ikarian Capital LLC grew its position in Kodiak Sciences by 15.4% in the 1st quarter. Ikarian Capital LLC now owns 476,586 shares of the company’s stock valued at $2,507,000 after acquiring an additional 63,705 shares during the last quarter. Sei Investments Co. purchased a new stake in Kodiak Sciences in the first quarter worth $595,000. Finally, RIA Advisory Group LLC purchased a new stake in Kodiak Sciences in the first quarter worth $489,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

NASDAQ:KOD opened at $2.71 on Monday. The firm has a 50-day simple moving average of $2.69 and a 200-day simple moving average of $3.50. Kodiak Sciences Inc. has a one year low of $1.37 and a one year high of $7.77. The firm has a market cap of $142.37 million, a P/E ratio of -0.61 and a beta of 2.35.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01. On average, research analysts predict that Kodiak Sciences Inc. will post -3.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright started coverage on shares of Kodiak Sciences in a research note on Thursday, September 5th. They issued a “neutral” rating and a $3.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.00.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.